The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies

  • STATUS
    Recruiting
  • End date
    Jun 5, 2025
  • participants needed
    45
  • sponsor
    Roshni Dasgupta
Updated on 19 February 2024
cancer
ct scan
metastasis
metastatic malignancy
pulmonary metastasis

Summary

Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospective feasibility study of pediatric patients with solid malignancies with or without lung metastatases who present at the time of initial diagnosis or relapse. These patients will receive a targeted dye to aid in the resection of these metastases. We plan to assess ICG as it relates to:

  1. Diagnostic accuracy using pathologic correlation as gold standard measure
  2. Short and long term event free and overall survival

Description

Patients diagnosed with solid malignancies or metastatic lesions who require clinically indicated resection will be identified by their Oncologist. The oncologist will inform the subject/family about the study and ask if they may be interested in participating. If the subject/family demonstrates potential interest in the study, the Pediatric Surgery Research team will discuss the risks and benefits of pre-operative ICG administration with the patients and enrollment.

Study subjects: All patients diagnosed with solid malignancies as well as those with metastatic disease distant from the primary tumor will be potentially eligible for the study. Diagnosis will be made:

  1. In a multimodal fashion including physical exam, radiologic evaluation (ultrasound, MRI, CT scan, etc), and sometimes biopsy.
  2. Prior to definitive surgical resection of the newly diagnosed malignancy

Details
Condition Metastasis, Brain Metastases, Liver Metastases, neoplasm metastasis, Brain Metastases, Liver Metastases, neoplasm metastasis, Primary Tumor, Solid Malignancies
Age 45years or below
Clinical Study IdentifierNCT04492735
SponsorRoshni Dasgupta
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

All patients with newly diagnosed solid, primary malignancies or their related
metastatic lesions
Diagnosis of primary or metastatic malignancy will be made by combination of
Clinical evaluation and physical exam
Radiologic study including ultrasound, CT scan, and/or MRI
Pathologic diagnosis after biopsy

Exclusion Criteria

Those patients and parents/guardians unwilling to provide consent/assent
Pregnant and/or women who are breast feeding
Patients with Iodine allergies
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.